Novo Nordisk Unveils Bold 2030 Strategy Amid Competitive Pressure and Investor Concerns
September 21, 2026
In a Capital Markets Day focused on growth, Novo Nordisk outlined a plan to launch more than five multi-blockbuster drugs annually by 2030, with a goal of over 150 billion Danish kroner in pipeline sales by 2035, driven by an expanded metabolic drug pipeline spanning obesity, diabetes, and other areas.
The company intends at least five Phase 3 trials in obesity and diabetes, plus an additional five Phase 3 studies in other therapeutic areas, as part of a broader diversification strategy.
Management signaled a strategic pivot to sustain growth by expanding the pipeline, aiming to restore growth and diversify beyond semaglutide-focused revenue.
Shares initially fell as much as about 7–8% in response to the announcements at the London Capital Markets Day.
Analysts noted a discrepancy between reported growth and adjusted figures, highlighting pricing pressure and mix as core concerns in the near term.
Investor focus shifted to questions about pricing power and future dealmaking ahead of Wegovy and Ozempic patent expiries, contributing to a stock pullback of up to around 9%.
Although positive news emerged from Phase 3 topline data for CagriSema, investors remained wary about long-term market share erosion and near-term commercialization hurdles.
Overall analyst sentiment cooled, with downgrades and valuation re-ratings reflecting muted medium-term growth prospects and pipeline lag.
The briefing took place during Capital Markets Day in London, underscoring a deliberate shift to sustain growth in a crowded competitive landscape.
A US regulatory decision for Cagri-Sema is anticipated in the fourth quarter, a potential catalyst for the obesity/multi-blockbuster strategy.
Novo’s GLP-1 franchise remains a smaller revenue contributor than Eli Lilly’s, which holds a roughly 2-to-1 sales advantage and stronger recent performance in obesity and diabetes therapies.
In Q2, Novo controlled about 39% of the obesity drug market while Eli Lilly held about 61%, signaling continued competitive pressure on Novo’s weight-management portfolio.
Summary based on 15 sources
Get a daily email with more EU News stories
Sources

Stock Titan • Sep 21, 2026
Highlights to be presented at Novo’s Capital Markets Day 2026
Investing.com • Sep 21, 2026
Novo Nordisk shares fall 6% as company sets 2030 growth targets
Business Standard • Sep 21, 2026
Novo Nordisk aims to launch more than five blockbuster drugs by 2030: CEO